For liver cancer! Keystone Pharmaceuticals PD-1 antibodies are qualified by the U.S. FDA for orphan drugs.
Jiahe Bio-Bio PD-1 Monoto-list application is to be included in the priority review.
PD-L1-CTLA-4 bispecific antibodies developed by Corning Jerry are about to enter clinical trials.
Establish a global coordinating body to strengthen global management of gene editing technologies.
PD-L1 Single Anti-Bavencio plus Asitini: Recommended by NICE in the UK as a first-line treatment for advanced kidney cancer.
Domestic PD-1 growth rate is amazing, the first half of sales close to the o drug year- through.
Roche PD-L1 monoanti-Tecentriq joint targeted therapy: FDA approved for treatment of advanced melanoma.
Anti-CD47 / PD-L1 Bispecific Antibody Clinical Trials: The first patient in China has entered the group.
The measures for change management after the drug is listed for public consultation.
Cinda PD-1 sales of 500 million in the second quarter.
Official interpretation of "Strengthening quality management and control of single-disease"
A large number of professional qualifications cancelled: medical representatives, health managers...
Cinda BioCD47/PD-L1 B2specific Antibody Phase I Clinical Study completed the first patient administration in China.
Cinda anti-CD47/PD-L1 bispecific antibody Phase I clinical completion of China's first patient administration.
A report on the management of perinatal anesthesia in patients with ultra-old patients with a full uterine double attachment excision.
Guidelines for drug clinical trial management (trial) announced during the outbreak of new crown pneumonia!
Health management map decryption: 3 years more than 100 investment three major track billions of dollars.
What new options are available for new drugs for Hodgkin's lymphoma after the PD-1 antibody fight?
Twenty-four regulations, such as the Code of Quality Management for Drug Clinical Trials, have been repealed.
Multiple feed plants are deeply managed! Multi-provincial environmental protection governance efforts unprecedented strengthening!